SEARCH

SEARCH BY CITATION

References

  • 1
    The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:23522363.
  • 2
    Wardlaw JM, Murray V, Berge E et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:23642372.
  • 3
    Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet 2010; 375:16951703.
  • 4
    Wardlaw JM, West TM, Sandercock PA, Lewis SC, Mielke O. Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation. J Neurol Neurosurg Psychiatry 2003; 74:452458.
  • 5
    von Kummer R, Meyding-Lamade U, Forsting M et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994; 15:915.
  • 6
    von Kummer R, Nolte PN, Schnittger H, Thron A, Ringelstein EB. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke. Neuroradiology 1996; 38:3133.
  • 7
    von Kummer R, Allen KL, Holle R et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997; 205:327333.
  • 8
    von Kummer R, Bourquain H, Bastianello S et al. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology 2001; 219:95100.
  • 9
    Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment – systematic review. Radiology 2005; 235:444453.
  • 10
    Wardlaw JM, Farrall AJ, Perry D et al. Factors influencing the detection of early computed tomography signs of cerebral ischemia. An internet-based, international multiobserver study. Stroke 2007; 38:12501256.
  • 11
    Brazzelli M, Sandercock PAG, Grazia Celani M et al. MRI versus CT for detection of acute vascular lesions in patients presenting with stroke symptoms. Stroke 2010; 41:e27e28.
  • 12
    Leys D, Ringelstein EB, Kaste M, Hacke W. Facilities available in European hospitals treating stroke patients. Stroke 2007; 38:29852991.
  • 13
    Kane I, Whiteley WN, Sandercock PA, Wardlaw JM. Availability of CT and MR for assessing patients with acute stroke. Cerebrovasc Dis 2008; 25:375377.
  • 14
    Barber PA, Hill MD, Eliasziw M et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005; 76:15281533.
  • 15
    Hand PJ, Wardlaw JM, Rowat AM, Haisma JA, Lindley RI, Dennis MS. Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient-related difficulties. J Neurol Neurosurg Psychiatry 2005; 76:15251527.
  • 16
    Schellinger PD. EPITHET: failed chance or new hope? Lancet Neurol 2008; 7:286287.
  • 17
    Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol 2006; 60:508517.
  • 18
    Hacke W, Albers G, Al Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:6673.
  • 19
    Furlan AJ, Eyding D, Albers GW et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS). Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:12271231.
  • 20
    Davis SM, Donnan G, Parsons MW et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299309.
  • 21
    Wardlaw JM, Murray VE, Berge E, del Zoppo GJ. Thrombolysis in acute ischaemic stroke. Cochrane Database Syst Rev 2009; (4):CD000213. doi: 10.1002/14651858.CD000213.pub2.
  • 22
    Mishra NK, Albers GW, Davis SM et al. Mismatch-based delayed thrombolysis. A meta-analysis. Stroke 2010; 41:e25e33.
  • 23
    Nagakane Y, Christensen S, Brekenfeld C et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke 2011; 42:5964.
  • 24
    Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry 2007; 78:485491.
  • 25
    Rivers CS, Wardlaw JM, Armitage P et al. Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke? Stroke 2006; 37:98104.
  • 26
    Zhao L, Barlinn K, Bag AK et al. Computed tomography perfusion prognostic maps do not predict reversible and irreversible neurological dysfunction following reperfusion therapies. Int J Stroke 2011; 6:544546.
  • 27
    Morcos SK, Thomsen HS, Exley CM. Contrast media: interactions with other drugs and clinical tests. Eur Radiol 2005; 15:14631468.
  • 28
    Pislaru S, Pislaru C, Szilard M, Arnout J, van de Werf F. In vivo effects of contrast media on coronary thrombolysis. J Am Coll Cardiol 1998; 32:11021108.
  • 29
    Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate DA. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents. J Am Coll Cardiol 1995; 25:10691075.
  • 30
    Dzialowski I, Puetz V, Buchan AM, Demchuk AM, Hill MD. Does the application of x-ray contrast agents impair the clinical effect of intravenous recombinant tissue-type plasminogen activator in acute ischemic stroke patients? Stroke 2012; 43:15671571.
  • 31
    Dani KA, Thomas RGR, Chappell FM et al. Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. Ann Neurol 2011; 70:384401.
  • 32
    Kane I, Carpenter T, Chappell F et al. Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke. Effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke 2007; 38:31583164.
  • 33
    Hjort N, Butcher K, Davis SM et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005; 36:388397.
  • 34
    Wintermark M, Albers GW, Alexandrov AV et al. Acute stroke imaging research roadmap. Stroke 2008; 39:16211628.
  • 35
    Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke. A systematic review. Stroke 2006; 37:13341339.
  • 36
    Ogata T, Nagakane Y, Christensen S et al. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. Stroke 2011; 42:15961601.
  • 37
    Schaefer PW, Barak ER, Kamalian S et al. Quantitative assessment of core/penumbra mismatch in acute stroke: CT and MR perfusion imaging are strongly correlated when sufficient brain volume is imaged. Stroke 2008; 39:29862992.
  • 38
    Campbell BC, Christensen S, Levi CR et al. Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke 2011; 42:34353440.
  • 39
    Bivard A, McElduff P, Spratt N, Levi C, Parsons M. Defining the extent of irreversible brain ischemia using perfusion computed tomography. Cerebrovasc Dis 2011; 31:238245.
  • 40
    Wintermark M, Flanders AE, Velthuis B et al. Perfusion-CT assessment of infarct core and penumbra. Receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37:979985.
  • 41
    McVerry F, The TMRC Acute Strike Study Collaborators. Perfusion CT in acute ischaemic stroke. Int J Stroke 2009; 4:3.
  • 42
    Calamante F, Christensen S, Desmond PM, Ostergaard L, Davis SM, Connelly A. The physiological significance of the time-to-maximum (Tmax) parameter in perfusion MRI. Stroke 2010; 41:11691174.
  • 43
    Takasawa M, Jones PS, Guadagno JV et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke 2008; 39:870877.
  • 44
    Olivot J-M, Mlynash M, Thijs VN et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009; 40:469475.
  • 45
    Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke 2010; 41:28172821.
  • 46
    Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging 2010; 32:10241037.
  • 47
    Lansberg MG, Lee J, Christensen S et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke 2011; 42:16081614.
  • 48
    Christensen S, Mouridsen K, Wu O et al. Comparison of 10 perfusion MRI parameters in 97 sub-6-hour stroke patients using voxel-based receiver operating characteristics analysis. Stroke 2009; 40:20552061.
  • 49
    Leeflang MM, Moons KG, Reitsma JB, Zwinderman AH. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem 2008; 54:729737.
  • 50
    Kudo K, Sasaki M, Yamada K et al. Differences in CT perfusion maps generated by different commercial software: quantitative analysis by using identical source data of acute stroke patients. Radiology 2010; 254:200209.
  • 51
    Coutts SB, Simon JE, Tomanek AI et al. Reliability of assessing percentage of diffusion-perfusion mismatch. Stroke 2003; 34:16811685.
  • 52
    Parsons M, Spratt N, Bivard A et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366:10991107.
  • 53
    Campbell BCV, Christensen S, Foster SJ et al. Visual assessment of perfusion-diffusion mismatch is inadequate to select patients for thrombolysis. Cerebrovasc Dis 2010; 29:592596.
  • 54
    Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005; 36:24002403.
  • 55
    Kharitonova T, Ahmed N, Thorén M et al. Hyperdense middle cerebral artery sign on admission CT scan – prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis 2009; 27:5159.
  • 56
    Kobayashi A, Wardlaw JM, Lindley RI, Lewis SC, Sandercock PAG, Czlonkowska A. Oxfordshire Community Stroke Project clinical stroke syndrome and appearances of tissue and vascular lesions on pre-treatment CT in hyperacute ischaemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3). Stroke 2009; 40:743748.
  • 57
    Kharitonova T, Thoren M, Ahmed N et al. Disappearing hyperdense middle cerebral artery sign in ischemic stroke patients treated with intravenous thrombolysis – clinical course and prognostic significance. J Neurol Neurosurg Psychiatry 2008; 80:273278.
  • 58
    Ciccone A, Valvassori L, Nichelatti M. SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. Int J Stroke 2011; 6:259265.
  • 59
    Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282:20032011.
  • 60
    Rha J, Saver JL. The impact of recanalization on ischemic stroke outcome. A meta-analysis. Stroke 2007; 38:967973.
  • 61
    Bastianello S, Pierallini A, Colonnese C et al. Hyperdense middle cerebral artery CT sign. Comparison with angiography in the acute phase of ischemic supratentorial infarction. Neuroradiology 1991; 33:207211.
  • 62
    Kim EY, Yoo E, Choi HY, Lee JW, Heo JH. Thrombus volume comparison between patients with and without hyperattenuated artery sign on CT. AJNR Am J Neuroradiol 2008; 29:359362.
  • 63
    Riedel CH, Jensen U, Rohr A et al. Assessment of thrombus in acute middle cerebral artery occlusion using thin-slice nonenhanced computed tomography reconstructions. Stroke 2010; 41:16591664.
  • 64
    Riedel CH, Zoubie J, Ulmer S, Gierthmuehlen J, Jansen O. Thin-slice reconstructions of nonenhanced CT images allow for detection of thrombus in acute stroke. Stroke 2012; 43:23192323.
  • 65
    Kirchhof K, Welzel T, Zoubaa S et al. New method of embolus preparation for standardized embolic stroke in rabbits. Stroke 2002; 33:23292333.
  • 66
    Liebeskind DS, Sanossian N, Yong WH et al. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke 2011; 42:12371243.
  • 67
    Kimura K, Iguchi Y, Shibazaki K, Watanabe M, Iwanaga T, Aoki J. M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke. Stroke 2009; 40:31303132.
  • 68
    Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes. Thromb Haemost 2009; 102:11691175.
  • 69
    Marder VJ, Chute DJ, Starkman S et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37:20862093.
  • 70
    TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312:932936.
  • 71
    Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976982.
  • 72
    Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19:802812.
  • 73
    Higashida RT, Furlan AJ. Trial design and reporting standards for intra-aterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34:19231924.
  • 74
    Noser EA, Shaltoni HM, Hall CE et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke 2005; 36:292296.
  • 75
    Tomsick T, Broderick J, Carrozella J et al. Revascularization results in the Interventional Management of Stroke II trial. Am J Neuroradiol 2008; 29:582587.
  • 76
    Tomsick T. TIMI, TIBI, TICI: I came, I saw, I got confused. AJNR Am J Neuroradiol 2007; 28:382384.
  • 77
    Arnold M, Nedeltchev K, Remonda L et al. Recanalisation of middle cerebral artery occlusion after intra-arterial thrombolysis: different recanalisation grading systems and clinical functional outcome. J Neurol Neurosurg Psychiatry 2005; 76:13731376.
  • 78
    Tan IY, Demchuk AM, Hopyan J et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. Am J Neuroradiol 2009; 30:525531.
  • 79
    Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011; 10:909921.
  • 80
    Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 2009; 132:22312238.
  • 81
    Whiteley W, Lindley R, Wardlaw J, Sandercock P, on behalf of the IST Collaborative Group. Third international stroke trial. Int J Stroke 2006; 1:172176.
  • 82
    Sandercock P, Lindley R, Wardlaw J et al. Update on the Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials 2011; 12:252.
  • 83
    Wardlaw JM, Sellar RJ. A simple practical classification of cerebral infarcts on CT and its interobserver reliability. AJNR Am J Neuroradiol 1994; 15:19331939.
  • 84
    Wardlaw JM, von Kummer R, Farrall AJ, Chappell FM, Hill M, Perry D. A large web-based observer reliability study of early ischaemic signs on computed tomography. The Acute Cerebral CT Evaluation Of Stroke Study (ACCESS). PLoS ONE 2010; 5:e15757. doi:10.1371/journal.pone.0015757.
  • 85
    Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355:16701674.
  • 86
    Rowat A, Graham C, Dennis M. Dehydration in hospital-admitted stroke patients: detection, frequency, and association. Stroke 2011; 43:857859.
  • 87
    van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 1990; 53:10801083.
  • 88
    Cordonnier C, Potter GM, Jackson CA et al. Improving interrater agreement about brain microbleeds. Development of the Brain Observer MicroBleed Scales (BOMBS). Stroke 2009; 49:9499.
  • 89
    Farrell C, Chappell F, Armitage PA et al. Development and initial testing of normal reference MR images for the brain at ages 65–70 and 75–80 years. Eur Radiol 2008; 19:177183.
  • 90
    Carpenter T, Armitage PA, Bastin ME, Wardlaw JM. DSC perfusion MRI – quantification and reduction of systematic errors arising in areas of reduced cerebral blood flow. Magn Reson Med 2006; 55:13421349.
  • 91
    Wu O, Ostergaard L, Weisskoff RM, Benner T, Rosen BR, Sorensen AG. Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med 2003; 50:164174.
  • 92
    Hand PJ. ‘Brain Attack’. A new approach to stroke and transient ischaemic attack. 2002; 1526.
  • 93
    Sandercock P, Lindley R, Wardlaw J, Whiteley W, Murray G, on behalf of The IST3 Collaborative Group. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a ‘thread’ of reports of the trial. Int J Stroke 2012; 7:186187.
  • 94
    International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1996; 349:15691581.